MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-10-2026
Sonoma Pharmaceuticals Operating Cycle 2011-2026 | SNOA
Annual Operating Cycle Sonoma Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 182 | 206 | 183 | 185 | 139 | 179 | 209 | 146 | 173 | 131 | 118 | 137 | 117 | 148 | 152 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 209 | 117 | 160 |
Quarterly Operating Cycle Sonoma Pharmaceuticals
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 177 | 141 | 175 | - | 190 | 195 | 200 | - | 223 | 215 | 181 | - | 201 | 215 | 162 | - | 243 | 64.5 | 85.3 | - | 193 | 215 | 196 | 172 | 208 | 146 | 152 | 129 | 168 | 149 | 134 | - | 151 | 153 | 159 | - | 172 | 61.8 | 82.3 | - | 171 | 62.3 | 58.6 | - | 126 | 44.3 | 61.9 | - | 136 | 38.6 | 56.1 | - | 152 | 44.7 | 2.55 K | - | 158 | 78.3 | 3.47 K | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.47 K | 38.6 | 267 |
Operating Cycle of other stocks in the Drug manufacturers industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
180 | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
55.1 | - | - | $ 36.6 M |  USA |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
117 | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
653 | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
121 | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
576 | - | - | $ 754 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
662 | $ 6.15 | 2.76 % | $ 91.4 M | USA |
 |
Agile Therapeutics
AGRX
|
146 | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
181 | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
61.7 | $ 2.85 | 0.18 % | $ 1.09 B | Canada |
 |
Athenex
ATNX
|
247 | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
153 | $ 35.22 | -0.48 % | $ 1.29 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
416 | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
152 | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
214 | - | -39.89 % | $ 27.7 M | USA |
 |
Bausch Health Companies
BHC
|
79.8 | $ 5.34 | -1.39 % | $ 1.98 B | Canada |
 |
Pacira BioSciences
PCRX
|
246 | $ 23.51 | -0.72 % | $ 1.09 B | USA |
 |
Organogenesis Holdings
ORGO
|
106 | $ 2.57 | -2.1 % | $ 326 M | USA |
 |
Canopy Growth Corporation
CGC
|
230 | $ 1.11 | -1.34 % | $ 119 M | Canada |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 3.59 | -2.32 % | $ 197 M | Canada |
 |
Jupiter Wellness
JUPW
|
132 | - | - | $ 33.6 M | USA |
 |
Tilray
TLRY
|
222 | $ 5.59 | -1.15 % | $ 3.45 B | Canada |
 |
Lannett Company
LCI
|
210 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.16 | 1.32 % | $ 111 M | Canada |
 |
Evolus
EOLS
|
134 | $ 6.59 | 0.23 % | $ 425 M | USA |
 |
Emergent BioSolutions
EBS
|
425 | $ 9.28 | 1.03 % | $ 496 M | USA |
 |
Veru
VERU
|
271 | $ 2.33 | 0.43 % | $ 34.1 M | USA |
 |
Assertio Holdings
ASRT
|
590 | $ 23.44 | -0.02 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
141 | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
239 | - | - | $ 1.42 B | USA |
 |
cbdMD
YCBD
|
152 | $ 0.81 | -2.08 % | $ 3.26 M | USA |
 |
PetIQ
PETQ
|
108 | - | 1.64 % | $ 400 M | USA |
 |
Recro Pharma
REPH
|
112 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
508 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
2.74 | $ 0.73 | -0.27 % | $ 36.5 M | USA |
 |
PLx Pharma
PLXP
|
113 | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
221 | $ 16.11 | - | $ 18.8 B | USA |
 |
Zomedica Corp.
ZOM
|
218 | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
14.6 K | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
72.5 | $ 0.74 | -2.56 % | $ 26.6 M | USA |
 |
China Pharma Holdings
CPHI
|
187 | $ 0.81 | 4.67 % | $ 3.48 M |  China |
 |
TherapeuticsMD
TXMD
|
3.34 K | $ 2.07 | -1.9 % | $ 23.9 M | USA |